| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454822 | Lung Cancer | 2015 | 24 Pages |
Abstract
Although the study did not meet the primary objective, both treatment groups demonstrated good safety-related feasibility and tolerability as adjuvant treatment in patients with completely resected Stage IB/II NSCLC.
Keywords
SAEDFSi.v.MedDRACTCAETEAEFeasibilityImmunohistochemistryIHCdisease-free survivaloverall survivalIntravenousAdjuvant treatmentTREATtreatment emergent adverse eventMedical Dictionary for Regulatory ActivitiesNon-small-cell lung cancerNSCLCadverse eventSerious adverse eventconfidence intervalCommon Terminology Criteria for Adverse EventsSingle nucleotide polymorphismPemetrexedSNP
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, Wolfgang Schuette, Jan Stöhlmacher, Jürgen R. Fischer, Julien Mazières, Christos Chouaid, Martin Wolf, Nuria Vinolas, Victoria Soldatenkova, Veronique Ripoche, Tuan Nguyen,